Crossref
Similarity Check
Powered by iThenticate

53998-Review.docx

Quotes Excluded
Bibliography Excluded

9%
SIMILAR

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 53998

Manuscript Type: CASE REPORT

Therapy-related acute promyelocytic leukemia with FMS-like tyrosine kinase 3-internal tandem duplication mutation in solitary bone plasmacytoma: A case report

Hong LL *et al*. t-APL in solitary bone plasmacytoma

Li-Li Hong, Xian-Fu Sheng, Hai-Feng Zhuang

Abstract

BACKGROUND

Therapy-related acute promyelocytic leukemia (t-APL) is a rare complication observed after solitary bone plasmacytoma (SBP), and SBP after radiotherapy evolving to APL

Match Breakdown

1 Crossref 90 words
Hyunjung Gu, Young Jin Kim, Woo-In Lee, Juhee Lee, Hwi-Joong Yoon, Tae Sung Park. "Therapy-related acute promyelo...   4%

◀ Match 1 of 3 ▶

● Crossref 90 words
Hyunjung Gu, Young Jin Kim, Woo-In Lee, Juhee Lee, Hwi-Joong Yoon, Tae Sung Park. "Therapy-related acute promye...   4%

● Crossref 20 words
Desiree H.-A. Skeete. "Myeloid Sarcoma of the Vagina : A Report of 2 Cases", Journal of Lower Genital Tract Disease, 04/   1%

● Internet 20 words
crawled on 12-Feb-2017
www.ashg.org   1%

Exclude Sources

Therapy-related acute promyelocytic leukemia with FLT3-ITD mutati

ALL   IMAGES   VIDEOS

12,400 Results   Any time ▾

Clinical impact of FLT3 mutation load in acute ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232262

Results. Internal tandem duplications of the FLT3 gene (FLT3-ITD) were detected in 47/147 (32.0%) and tyrosine kinase domain **mutations** (FLT3-TKD) in 19/147 (12.9%) patients.FLT3-ITD or FLT3-TKD **mutation** status did not have a significant prognostic impact, whereas FLT3-ITD **mutation** load, as defined by a **mutation**/wild-type ratio of less than 0.5 was associated with trends to a better 2-year ...

Cited by: 70   Author: Susanne Schnittger, Ulrike Bacher, Claud...
Publish Year: 2011

A case of therapy-related acute myeloid leukemia with inv ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464341

Sep 25, 2012 · INTRODUCTION. **Therapy-related acute** myeloid **leukemia** (t-AML) caused by radioactive iodine (RAI) occurs in less than 2% of thyroid cancer patients and is associated with a poor therapeutic response and prognosis [1-3].Many cases of t-AML have occurred in >50-year-old patients after they received a cumulative radioiodine dose of more than 800 mCi, with intervals of less than 12 ...

Cited by: 3   Author: Ji Hun Jeong, Jeong Yeal Ahn, Soon Ho ...
Publish Year: 2012

Acute myeloid leukemia: 2019 update on risk-stratification ...

Therapy-related acute promyelocytic leukemia with FMS-like tyrosin

Sign in

ALL   IMAGES   VIDEOS

Add the Give with Bing ext

6,440 Results   Any time ▼

Hyperthyroidism with concurrent FMS-like tyrosine kinase 3 ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881699

Hyperthyroidism complicated with **leukemia** is even rarer, particularly **acute promyelocytic leukemia** (APL) **with FMS-like tyrosine kinase 3-internal tandem duplication** (FLT3-ITD). The c-erb-A protooncogene, a thyroid hormone receptor analog, is located in ...

Cited by: 2   Author: Yajian Jiang, Keyue Hu, Wanzhuo Xie, Gaof...

Publish Year: 2014

Internal tandem duplication and Asp835 mutations of the ...

https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.11636

Aug 20, 2003 · The **FMS-like tyrosine kinase** 3 (FLT3) gene, which is located on chromosome 13q12 in humans, 1 encodes a Class III receptor **tyrosine kinase** and plays an important role in hematopoiesis. 2 Two distinct types of FLT3-activating mutations have been reported in 30% of patients with **acute** myeloid **leukemia** (AML). The most common FLT3 mutations (incidence rate, ≈20−25%) in patients with AML ...

Cited by: 109   Author: Lee-Yung Shih, Lee-Yung Shih, Ming-Chung ...

Publish Year: 2003

FLT3 mutations in myelodysplastic syndrome and chronic ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085099

FMS-like tyrosine kinase III (FLT3) mutations occur in one-third of **acute** myeloid **leukemia** (AML) patients and predict poor outcome.The incidence and impact of FLT3 in myelodysplastic syndrome (MDS)

Search Tools

Turn off Hover Translation (关闭取词)

Therapy-related acute promyelocytic leukemia with FMS-like tyrosine kir

ALL　　IMAGES　　VIDEOS

6,430 Results　　Any time ▾

Hyperthyroidism with concurrent FMS-like tyrosine kinase 3 ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881699

Hyperthyroidism complicated with **leukemia** is even rarer, particularly **acute promyelocytic leukemia** (APL) **with FMS-like tyrosine kinase 3-internal tandem duplication** (FLT3-ITD). The c-erb-A protooncogene, a thyroid hormone receptor analog, is located in ...

Cited by: 2　　　　Author: Yajian Jiang, Keyue Hu, Wanzhuo Xie, G...
Publish Year: 2014

Internal tandem duplication and Asp835 mutations of the ...

https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.11636

Aug 20, 2003 · The **FMS-like tyrosine kinase** 3 (FLT3) gene, which is located on chromosome 13q12 in humans, 1 encodes a Class III receptor **tyrosine kinase** and plays an important role in hematopoiesis. 2 Two distinct types of FLT3-activating mutations have been reported in 30% of patients with **acute** myeloid **leukemia** (AML). The most common FLT3 mutations (incidence rate, ≈20–25%) in patients with AML ...

Cited by: 109　　　　Author: Lee-Yung Shih, Lee-Yung Shih, Ming-Ch...
Publish Year: 2003

FLT3 mutations in myelodysplastic syndrome and chronic ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085099

FMS-like tyrosine kinase III (FLT3) mutations occur in one-third of **acute** myeloid **leukemia** (AML) patients and predict poor outcome.The incidence and impact of FLT3 in myelodysplastic syndrome (MDS) and chronic myelomonocytic **leukemia** (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with FLT3 mutations at diagnosis.

Cited by: 62　　　　Author: Naval Daver, Paolo Strati, Elias Jabbour, ...
Publish Year: 2013

FLT3 internal tandem duplication mutations in acute ...

https://www.researchgate.net/publication/12237052...

Results: **Fms-like tyrosine kinase 3 internal tandem duplication** mutations were observed in 20%, **tyrosine kinase** domain **mutation** in 4% and dual mutations in 0.3% of the analyzed cases.